Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?
The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease--brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.